You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Phage Display Peptide Probes for Imaging Early Response to Cancer Therapy

    SBC: ACADUCEUS PHARMACEUTICS, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The ultimate goal of this SBIR proposal is to develop novel molecular imaging markers for monitoring tumor early response and efficacy to anti-angiogenic treatment regimens. Anti-angiogenic therapy represents an exciting advance in the management of cancer. Targeting of the vasculature has been shown to benefit patients with several types of malignancies. Hundr ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  2. Real-time PET guided radiation therapy for cancer treatment

    SBC: REFLEXION MEDICAL, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The effectiveness of radiation therapy for lung cancer treatment can be significantly improved if radiation dose can be safely escalated. The main limitation to dose escalation is tumor location uncertainty during treatment due to patient respiration. In addition to geometric changes, tumor hypoxia is a leading cause of treatment failure. If dose can be escalat ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  3. Virus-Targeted Therapy for Malignancies

    SBC: Phoenicia Biosciences, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): Epstein-Barr virus (EBV) is associated with a number of human malignancies for which there are presently few effective treatments. Lymphoid malignancies caused by, or associated with, Epstein-Barr virus include Burkitt's lymphoma, T/NK lymphomas, some T- and B-cell lymphomas, approximately half of Hodgkin's lymphomas and all post-transplant lymphopro ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  4. Rapid Testing of Drug-Resistant BCR-ABL(+)Leukemia Cells

    SBC: BIOSENSE TECHNOLOGIES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): Resistance to chemotherapeutic drugs is an ongoing problem that results in eventual treatment failures or suboptimal patient outcomes. In cancer cells treated with drugs to which they are sensitive, the stress responseis the first step in the subsequent cascade leading to cell death (apoptotic, necrotic or autophagy). The recent availability of a sensing modali ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  5. Automatic Segmentation of Organs in Computed Tomography for Radiation Therapy Pla

    SBC: MEDICAL VISION SYSTEMS            Topic: NCI

    DESCRIPTION (provided by applicant): Medical Vision Systems has developed a new image segmentation technology that improves the accuracy and robustness of automated medical image segmentation. Our commercial goal is to offer a product that produces accurate, fast, fully automatic segmentations at low cost to aid the Intensity Modulated Radiation Therapy (IMRT) treatment of prostate cancer. The us ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  6. Characterization of a GPCR-blocking antibody for the treatment of breast cancer.

    SBC: EXPRESSION DRUG DESIGN LLC            Topic: NCI

    DESCRIPTION (provided by applicant): G protein-coupled receptors (GPCRs) represent a diverse family of cell surface receptors that mediate important biological responses in nearly all cells. These responses include proliferation, migration, tissue invasion, and cell survival. As such, this large, ~700 member family represents the most attractive single family of drug targets for a variety of dise ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  7. Multiparameter Assay for Mechanistic Understanding of Carcinogens

    SBC: PRIMITY BIO, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): The determination of carcinogenic activity in experimental compounds is a long and expensive process that negatively impacts many core industries and can threaten human health. Faster, more reliable methods that can beused to accurately determine human oncogenic activity are needed to rapidly identify environmental problems and reduce the reliance on animal mod ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  8. Utrasensitive bioassays using palladium catalyzed chemical amplification

    SBC: BIOFORMATIX, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): We propose to use novel Palladium Catalyzed Chemical Amplification (PdCCA) technology to develop ultra-sensitive bioassays that can detect very low concentrations of tumor biomarkers in blood. PdCCA is a generic technology that can be universally applied to different assay platforms. In the bioassay application considered here it uses a detection antibody labe ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  9. A new small molecule targeting agent and therapeutic for non-Hodgkin's lymphoma

    SBC: Shal Technologies, Inc.            Topic: NCI

    DESCRIPTION (provided by applicant): The goal of this SBIR project is to complete the preclinical studies required to submit an IND application for a promising new therapeutic (SH7139) for non-Hodgkin's lymphoma so as to be able to advance this drug into clinical trials. SH7139 is a selective high affinity ligand (SHAL) that was designed to target a unique site on HLA-DR10, a protein receptor ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. Global Proteomic Screening by MALDI Spectrometric Imaging of Protein-Bead Arrays

    SBC: AMBERGEN, INC            Topic: NCI

    DESCRIPTION (provided by applicant): Sequencing of the human genome has led to a new and even more ambitious goal - characterization of the human proteome. Such an endeavor involves not only understanding the function of hundreds of thousands of differentproteins expressed in human cells but also characterizing the millions of potential interactions that can occur with other cellular and extracel ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government